Abstract
Objectives Blood pressure is the leading global cause of mortality, and its prevalence is increasing in children and adolescents. Aortic blood pressure (BP) is lower than brachial BP in adults. We aimed to assess the extent of this difference and its impact on the diagnosis of hypertension among adolescents.
Methods We used data from 3850 participants from a UK cohort of births in the early 1990s in the Southwest of England, who attended their ∼17 year follow-up and had valid measures of brachial and aortic BP at that clinic (mean(SD) age 17.8(0.4)y, 66% female). Data are presented as mean differences [95% prediction intervals] for both sexes.
Results Aortic systolic BP was lower than brachial systolic BP (male, -22.3[-31.2, - 13.3]mmHg; female, -17.8[-25.5, -10.0]mmHg). Differences between aortic and brachial diastolic BP were minimal. Based on brachial BP measurements, 101 males (6%) and 22 females (1%) were classified as hypertensive. In contrast, only nine males (<1%) and 14 females (<1%) met the criteria for hypertension based on aortic BP, and the predictive value of brachial BP for aortic hypertension was poor (positive predictive value = 13.8%). Participants with aortic hypertension had a higher left ventricular mass index than those with brachial hypertension.
Conclusions Brachial BP substantially overestimates aortic BP in adolescents due to marked aortic-to-brachial pulse pressure amplification. The use of brachial BP measurement may result in an overdiagnosis of hypertension during screening in adolescence.
Competing Interest Statement
GDS reports Scientific Advisory Board Membership for Relation Therapeutics and Insitro. NC ? Receives remuneration for membership of data monitoring and safety committees for trials sponsored by AstraZeneca pharmaceuticals.
Funding Statement
Cardiovascular measurements at age 17 were supported by grants from the Wellcome Trust (086676/7/08/Z) and the British Heart Foundation (PG/06/145 & CS/15/6/31468 & SP/F/21/150020). GDS, LDH and DL work within the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00011/1&6).The UK Medical Research Council and Wellcome Trust (102215/2/13/2), together with the University of Bristol, provide core support for the ALSPAC study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the ALSPAC Law and Ethics Committee and Local Research Ethics Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding Cardiovascular measurements at age 17 years were supported by grants from the Wellcome Trust (086676/7/08/Z) and the British Heart Foundation (PG/06/145 & CS/15/6/31468 & SP/F/21/150020). Drs. Davey Smith, Howe, and Lawlor worked within the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00011/1&6). The UK Medical Research Council and Wellcome Trust (102215/2/13/2) together with the University of Bristol provided core support for the ALSPAC study. The other authors declare no relevant financial relationships.
Role of the Funder/Sponsor: The funders had no role in the design or conduct of the study.
Conflict of Interest Disclosures Dr Davey Smith reports Scientific Advisory Board Membership for Relation Therapeutics and Insitro. Dr Chaturvedi receives remuneration for membership of data monitoring and safety committees for trials sponsored by AstraZeneca pharmaceuticals. The other authors have no relevant conflicts to report.
updated version revised for new submission. Some revisions to text and figures.
Data Availability
Access to ALSPAC data is through a system of managed open access (http://www.bristol.ac.uk/alspac/researchers/access/).
